Synonyms: MMV688756 | PF-02341272 | PNU-100480 | U-100480
Compound class:
Synthetic organic
Comment: Originally developed by Upjohn (later incorporated into Pfizer), sutezolid is an oxazolidinone class antibacterial with potent antimycobacterial activity [1]. It is being clinically evaluated as a treatment for tuberculosis (TB).
Sutezolid is included in the Medicines for Malaria (MMV) and Drugs for Neglected Diseases Initiative (DNDi) Pandemic Response Box. |
|
References |
1. Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS et al.. (1996)
Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem, 39 (3): 680-5. [PMID:8576910] |
2. Kim DH, Kim SY, Koh WJ, Jhun BW. (2021)
In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother, 65 (7): e0230620. [PMID:33903101] |
3. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS. (2007)
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell, 26 (3): 393-402. [PMID:17499045] |
4. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y et al.. (2014)
Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One, 9 (4): e94462. [PMID:24732289] |